INDICATIONS AND USAGE（适应症）

YONDELIS® is indicated for the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen.

DOSAGE（服用剂量）

The recommended dose is 1.5 mg/m2 administered as an intravenous infusion over 24 hours through a central venous line every 21 days (3 weeks), until disease progression or unacceptable toxicity.

Hepatic Impairment: The recommended dose is 0.9 mg/m2 in patients with moderate hepatic impairment (bilirubin levels greater than 1.5 times to 3 times the upper limit of normal, and AST and ALT less than 8 times the upper limit of normal). Do not administer YONDELIS to patients with severe hepatic impairment (bilirubin levels above 3 times the upper limit of normal, and any AST and ALT).

ADVERSE REACTIONS（不良反应）

Anaphylaxis

Neutropenic Sepsis

Rhabdomyolysis

Hepatotoxicity

Cardiomyopathy

Capillary Leak Syndrome

Extravasation Resulting in Tissue Necrosis

For full information, please refer to:

https://nctr-crs.fda.gov/fdalabel/services/spl/set-ids/472bd78e-be17-4b9d-90f4-9482c3aec9ff/spl-doc?hl=Yondelis

Yondelisinformation